Despite the overall favorable survival and available targeted treatments, in particular for estrogen receptor (ER)-positive or HER2-positive breast cancers, resistance to treatment is well recognized and novel potentially targetable pathways are needed [2]. The gene discussed is ESR1; the disease is breast carcinoma.